-- RemeGen (HKG:9995) said China's drug regulator approved its Disitamab Vedotin for the treatment of a type of bladder cancer, according to a Hong Kong bourse filing Friday.
Shares of the firm gained over 4% in morning trade Monday.
The drug was approved in combination with toripalimab for the treatment of urothelial carcinoma which expresses the HER2 protein.
The approval marks the fifth indication for Disitamab Vedotin in China.
Sheffield Green (SGX:SGR) rebranded its training subsidiary, Wind Asia Training and Stier Training Services to Trainergy, according to a Tuesday filing with the Singapore Exchange.Shares of the human resource services provider were down over 5% in Wednesday trading.The strategic move will unify the division to meet global demand for skilled labor in the global energy sector.Trainergy provides training and competency services across several sectors.
Producer input prices in the UK increased 5.4% year over year in March, following a revised 0.7% gain in February, data from the Office for National Statistics showed Wednesday.Meanwhile, producer output or factory gate prices jumped 2.6% annually, against the revised 1.8% rise earlier.On a monthly basis, producer input prices climbed 4.4% in March, compared with the revised 0.9% increase previously and the forecast of a 2.8% gain. Monthly factory gate prices edged up 0.9%, versus a 0.5% decline earlier and a projected 1% growth.
Far East Smarter Energy's (SHA:600869) attributable profit rose 110% to 96.6 million yuan in the first quarter from 45.9 million yuan in the year-ago period, according to a Wednesday filing with the Shanghai bourse.Earnings per share at the smart energy services company increased 104% to 0.0422 yuan from 0.0207 yuan in the prior-year period.Operating income grew 9.3% year over year to 5.32 billion yuan from 4.87 billion yuan.Shares increased 9% during afternoon trading on Wednesday.